• Wen Wen, Hua Fan, Shenghui Zhang, Siqi Hu, Chen Chen, Jiake Tang, Yao You, Chunyi Wang, Jie Li, Lin Luo, Yongran Cheng, Mengyun Zhou, Xuezhi Zhao, Tao Tan, Fangfang Xu, Xinyan Fu, Juan Chen, Peng Dong, Xingwei Zhang, Mingwei Wang, and Yan Feng.
• Department of Cardiology, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, 313000, Zhejiang, China.
• Am. J. Med. Sci. 2024 Dec 1; 368 (6): 557568557-568.

AbstractNon-alcoholic fatty liver disease (NAFLD) is closely related to metabolic syndrome and remains a major global health burden. The increased prevalence of obesity and type 2 diabetes mellitus (T2DM) worldwide has contributed to the rising incidence of NAFLD. It is widely believed that atherosclerotic cardiovascular disease (ASCVD) is associated with NAFLD. In the past decade, the clinical implications of NAFLD have gone beyond liver-related morbidity and mortality, with a majority of patient deaths attributed to malignancy, coronary heart disease (CHD), and other cardiovascular (CVD) complications. To better define fatty liver disease associated with metabolic disorders, experts proposed a new term in 2020 - metabolic dysfunction associated with fatty liver disease (MAFLD). Along with this new designation, updated diagnostic criteria were introduced, resulting in some differentiation between NAFLD and MAFLD patient populations, although there is overlap. The aim of this review is to explore the relationship between MAFLD and ASCVD based on the new definitions and diagnostic criteria, while briefly discussing potential mechanisms underlying cardiovascular disease in patients with MAFLD.Copyright © 2024 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.

23 keywords...

hide…